Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brandi Egizio

Physician Assistant Cedar Park, TX Physician Assistant

NPI 1043229107 CMS profile 11057266

1515 Medical Pkwy Ste 100, Cedar Park, TX 78613

Open in the dashboard

General payments

$15,153

589 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brandi Egizio of Cedar Park, TX is reported in the CMS Open Payments database as having received $15,153 across 589 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,976 177
2024 General $4,435 187
2023 General $4,111 156
2022 General $2,174 54
2021 General $456 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandi Egizio
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Brandi Egizio were reported at $3,976. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Brandi Egizio Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $456 $132 $37–$438 $132
2022 $2,174 $155 $48–$522 $149
2023 $4,111 $167 $52–$557 $160
2024 $4,435 $178 $55–$600 $164
2025 $3,976 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,853 126 payments
  2. Janssen Biotech, Inc. $1,812 69 payments
  3. Genzyme Corporation $1,397 35 payments
  4. Pfizer Inc. $1,126 52 payments
  5. Regeneron Pharmaceuticals, Inc. $927 7 payments
  6. Regeneron Healthcare Solutions, Inc. $920 50 payments
  7. Novartis Pharmaceuticals Corporation $755 36 payments
  8. LEO Pharma Inc. $728 37 payments
  9. Amgen Inc. $558 19 payments
  10. E.R. Squibb & Sons, L.L.C. $473 30 payments
  11. Other $3,603 128 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,573 580 payments
  2. Education $580 9 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,954 68 payments
  2. RINVOQ $1,755 81 payments
  3. DUPIXENT Immunology $1,489 26 payments
  4. DUPIXENT Inflammation And Immunology $1,168 32 payments
  5. CIBINQO $903 48 payments
  6. ADBRY $728 37 payments
  7. SKYRIZI $645 27 payments
  8. LITFULO $614 38 payments
  9. COSENTYX $569 27 payments
  10. Otezla $558 19 payments
  11. Other $6,019 268 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

413

Median for Physician Assistant: 241

Drug cost

$8,767

Median for Physician Assistant: $4,110

Branded share of claims

3.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 36 $1,760
Doxycycline Hyclate Generic 75 $1,247
Fluorouracil Generic 17 $1,136
Ketoconazole Generic 59 $1,080
Metronidazole Generic 23 $938
Triamcinolone Acetonide Generic 60 $768
Fluocinonide Generic 23 $637
Minoxidil Generic 34 $283
Mupirocin Generic 34 $258
Clindamycin Phosphate Generic 12 $249

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$81,443

Of which drugs: $329

Medicare patients

444

Average age 74

Services billed

2,321

320 women, 124 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 43%
Ischemic heart disease 21%
Diabetes 18%
Depression 17%
Osteoporosis 17%
Atrial fibrillation 14%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 18 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $475
  • Regeneron Pharmaceuticals, Inc. $257
  • Regeneron Healthcare Solutions, Inc. $134
$950 — —
RINVOQ
  • AbbVie, Inc. $531
$531 — —
TREMFYA
  • Janssen Biotech, Inc. $484
$484 — —
ADBRY
  • LEO Pharma Inc. $350
$350 — —
SKYRIZI
  • AbbVie, Inc. $268
$268 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

589 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record